CAO Kathryn Romano sells 12,500 shares at blended avg $272.14 for $3.4M, reducing holdings 40.2%
Kathryn Romano, Chief Accounting Officer at Krystal Biotech, executed 7 separate sales totaling 12,500 shares for $3,401,705.16 on 2026-02-09, reducing her holdings from 31.1K to 18.6K shares (a 40.2% reduction). The blended average price of $272.14 is near the current price of $272.65, and the stock is currently -6.6% from its 52-week high of $291.93, having risen 35.5% over the past 90 days. Notably, across her cross-ticker track record, Romano's 17 prior sells showed an 88.24% well-timed rate at the 90-day mark (higher % indicates better timing as stock fell after), and her 5 prior sells at KRYS were all well-timed at the 90-day horizon (averaging -5.8% 90-day returns after sale, with 2024-02-28 sales ranging from -2.5% to -7.4%). The substantial size and magnitude of this concentrated sale—40%+ of holdings liquidated at near-peak prices—combined with the insider's established track record of well-timed exit decisions at this ticker, warrants close attention to forward guidance and operational metrics.